David Lebowitz

Gavin Clark-Gartner

Jessica Fye

Tazeen Ahmad

Derek Archila

Leland Gershell

Li Wang Watsek

Paul Choi

Yaron Werber

Alexander Thompson

Dingding Shi

Joseph Schwartz

Kelly Shi

Luca Issi

Vikram Purohit

Alex Thompson

Daniel Bronder

Eliana Merle

Ellie Merle

Joori Park

Kyuwon Choi

Maxwell Skor

Simona Stan

Yun Zhong

- Ascendis Pharma is experiencing increasing **revenue generation** and expects to achieve **positive cash contribution quarter by quarter**, aiming for financial independence.  **[1612042_tx_381577_0]** 
- The company's YORVIPATH launch is performing well, with a **$5 billion potential peak sales** target for hypoparathyroidism and strong IP protection until **2042**.  **[1612042_tx_381577_0]** **[1612042_tx_381577_1]** 
- Ascendis Pharma anticipates FDA PDUFA for TransCon CNP by the end of November, highlighting its differentiation through continuous exposure and clinical benefits beyond linear growth.  **[1612042_tx_381577_0]** **[1612042_tx_381577_5]** 
- The company plans to expand its pipeline, leveraging its TransCon technology for new compounds and potential out-licensing opportunities in large indications like cardiovascular diseases.  **[1612042_tx_381577_0]** **[1612042_tx_381577_8]**

Ascendis Pharma Discusses Product Launches and Financial Independence at Wells Fargo Healthcare Conference

Ascendis Pharma (ASND)